{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T07:53:07Z","timestamp":1794383587285,"version":"4.9.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["8887.369851\/2019-00"],"award-info":[{"award-number":["8887.369851\/2019-00"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["130766\/2021-6"],"award-info":[{"award-number":["130766\/2021-6"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo (FAPESP, S\u00e3o Paulo State, Brazil), and Instituto Nacional de Ci\u00eancia e Tecnologia Translacional em Medicina","award":["CNPq\/FAPESP 14\/50891-1"],"award-info":[{"award-number":["CNPq\/FAPESP 14\/50891-1"]}]},{"name":"University Global Partnership Network","award":["Global Priorities in Cannabinoid Research Excellence Program"],"award-info":[{"award-number":["Global Priorities in Cannabinoid Research Excellence Program"]}]},{"name":"Pr\u00f3-Reitoria de Pesquisa da USP","award":["18.1.796.60.2 grupo 057"],"award-info":[{"award-number":["18.1.796.60.2 grupo 057"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This study aimed to assess the ultrapure cannabidiol (CBD) antibacterial activity and to investigate the antibacterial activity of the combination CBD\u2009+\u2009polymyxin B (PB) against Gram-negative (GN) bacteria, including PB-resistant Gram-negative bacilli (GNB). We used the standard broth microdilution method, checkerboard assay, and time-kill assay. CBD exhibited antibacterial activity against Gram-positive bacteria, lipooligosaccharide (LOS)-expressing GN diplococcus (GND) (\n                    <jats:italic>Neisseria gonorrhoeae<\/jats:italic>\n                    ,\n                    <jats:italic>Neisseria meningitidis<\/jats:italic>\n                    ,\n                    <jats:italic>Moraxella catarrhalis<\/jats:italic>\n                    ), and\n                    <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                    , but not against GNB. For most of the GNB studied, our results showed that low concentrations of PB (\u2264\u20092\u00a0\u00b5g\/mL) allow CBD (\u2264\u20094\u00a0\u00b5g\/mL) to exert antibacterial activity against GNB (e.g.,\n                    <jats:italic>Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii<\/jats:italic>\n                    ), including PB-resistant GNB. CBD\u2009+\u2009PB also showed additive and\/or synergistic effect against LOS-expressing GND. Time-kill assays results showed that the combination CBD\u2009+\u2009PB leads to a greater reduction in the number of colony forming units per milliliter compared to CBD and PB alone, at the same concentration used in combination, and the combination CBD\u2009+\u2009PB was synergistic for all four PB-resistant\n                    <jats:italic>K. pneumoniae<\/jats:italic>\n                    isolates evaluated. Our results show that CBD has translational potential and should be further explored as a repurposed antibacterial agent in clinical trials. The antibacterial efficacy of the combination CBD\u2009+\u2009PB against multidrug-resistant and extensively drug-resistant GNB, especially PB-resistant\n                    <jats:italic>K. pneumoniae<\/jats:italic>\n                    , is particularly promising.\n                  <\/jats:p>","DOI":"10.1038\/s41598-022-10393-8","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T13:03:44Z","timestamp":1650373424000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Potential cannabidiol (CBD) repurposing as antibacterial and promising therapy of CBD plus polymyxin B (PB) against PB-resistant gram-negative bacilli"],"prefix":"10.1038","volume":"12","author":[{"given":"Nath\u00e1lia","family":"Abichabki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu\u00edsa V.","family":"Zacharias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nat\u00e1lia C.","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Bellissimo-Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda L.","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhohann R. L.","family":"Benzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T\u00e2nia M. C.","family":"Ogasawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseane C.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila M.","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando R.","family":"Pavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo R. L.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme T. P.","family":"Brancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto \u00da. L.","family":"Braga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio W.","family":"Zuardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime E. C.","family":"Hallak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A. S.","family":"Crippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera L.","family":"Lanchote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Cant\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana L\u00facia C.","family":"Darini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo N.","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,19]]},"reference":[{"key":"10393_CR1","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1586\/eri.13.12","volume":"11","author":"JN Pendleton","year":"2013","unstructured":"Pendleton, J. N., Gorman, S. P. & Gilmore, B. F. Clinical relevance of the ESKAPE pathogens. Expert Rev. Anti. Infect. Ther. 11, 297\u2013308 (2013).","journal-title":"Expert Rev. Anti. Infect. Ther."},{"key":"10393_CR2","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos, A. P. et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 18, 268\u2013281 (2012).","journal-title":"Clin. Microbiol. Infect."},{"key":"10393_CR3","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1128\/CMR.00064-16","volume":"30","author":"L Poirel","year":"2017","unstructured":"Poirel, L., Jayol, A. & Nordmann, P. Polymyxins: Antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes. Clin. Microbiol. Rev. 30, 557\u2013596 (2017).","journal-title":"Clin. Microbiol. Rev."},{"key":"10393_CR4","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1093\/cid\/ciab295","volume":"72","author":"PD Tamma","year":"2012","unstructured":"Tamma, P. D. et al. Infectious Diseases Society of America Guidance on the treatment of extended-spectrum \u03b2-lactamase producing enterobacterales (ESBL-E), carbapenem-resistant enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR- P. aer. Clin. Infect. Dis. 72, 1109\u20131116 (2012).","journal-title":"Clin. Infect. Dis."},{"key":"10393_CR5","unstructured":"World Health Organization. World Health Organization Model List of Essential Medicines\u201422nd List. (2021)."},{"key":"10393_CR6","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","volume":"18","author":"E Tacconelli","year":"2018","unstructured":"Tacconelli, E. et al. Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect. Dis. 18, 318\u2013327 (2018).","journal-title":"Lancet Infect. Dis."},{"key":"10393_CR7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ejphar.2012.09.053","volume":"697","author":"T Barichello","year":"2012","unstructured":"Barichello, T. et al. Cannabidiol reduces host immune response and prevents cognitive impairments in Wistar rats submitted to pneumococcal meningitis. Eur. J. Pharmacol. 697, 158\u2013164 (2012).","journal-title":"Eur. J. Pharmacol."},{"key":"10393_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2018.02009","volume":"9","author":"JA Crippa","year":"2018","unstructured":"Crippa, J. A., Guimar\u00e3es, F. S., Campos, A. C. & Zuardi, A. W. Translational investigation of the therapeutic potential of cannabidiol (CBD): Toward a new age. Front. Immunol. 9, 1\u201316 (2018).","journal-title":"Front. Immunol."},{"key":"10393_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2020.00124","volume":"11","author":"T Cassano","year":"2020","unstructured":"Cassano, T. et al. From Cannabis sativa to cannabidiol: Promising therapeutic candidate for the treatment of neurodegenerative diseases. Front. Pharmacol. 11, 1\u201310 (2020).","journal-title":"Front. Pharmacol."},{"key":"10393_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcimb.2019.00324","volume":"9","author":"US Kosgodage","year":"2019","unstructured":"Kosgodage, U. S. et al. Cannabidiol is a novel modulator of bacterial membrane vesicles. Front. Cell. Infect. Microbiol. 9, 1\u201313 (2019).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10393_CR11","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1021\/np8002673","volume":"71","author":"G Appendino","year":"2008","unstructured":"Appendino, G. et al. Antibacterial cannabinoids from Cannabis sativa: A structure-activity study. J. Nat. Prod. 71, 1427\u20131430 (2008).","journal-title":"J. Nat. Prod."},{"key":"10393_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/BF00399444","volume":"42","author":"B van Klingeren","year":"1976","unstructured":"van Klingeren, B. & ten Ham, M. Antibacterial activity of \u03949-tetrahydrocannabinol and cannabidiol. Antonie Van Leeuwenhoek 42, 9\u201312 (1976).","journal-title":"Antonie Van Leeuwenhoek"},{"key":"10393_CR13","unstructured":"Andrade, L. N. et al. Antimicrobial activity of cannabidiol against Eskape pathogens: Inhibitory and bactericidal activity against vancomycin-resistant Enterococcus faecium, vancomycin-intermediate Staphylococcus aureus, and methicillin-resistant S. aureus. in ASM MICROBE 2018 (2018)."},{"key":"10393_CR14","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1021\/acsinfecdis.9b00419","volume":"6","author":"MA Farha","year":"2020","unstructured":"Farha, M. A. et al. Uncovering the hidden antibiotic potential of cannabis. ACS Infect. Dis. 6, 338\u2013346 (2020).","journal-title":"ACS Infect. Dis."},{"key":"10393_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biom10060900","volume":"10","author":"LD Martinenghi","year":"2020","unstructured":"Martinenghi, L. D., J\u00f8nsson, R., Lund, T. & Jenssen, H. Isolation, purification, and antimicrobial characterization of cannabidiolic acid and cannabidiol from Cannabis sativa L. Biomolecules 10, 1\u201316 (2020).","journal-title":"Biomolecules"},{"key":"10393_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-020-01530-y","author":"MAT Blaskovich","year":"2021","unstructured":"Blaskovich, M. A. T. et al. The antimicrobial potential of cannabidiol. Commun. Biol. https:\/\/doi.org\/10.1038\/s42003-020-01530-y (2021).","journal-title":"Commun. Biol."},{"key":"10393_CR17","unstructured":"Abichabki, N. et al. Cannabidiol synergic antimicrobial activity combined with polymyxin B (PB) against PB susceptible and resistant Gram-Negative bacilli. in 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2020 (2020)."},{"key":"10393_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.mib.2020.05.012","volume":"57","author":"GJ Sullivan","year":"2020","unstructured":"Sullivan, G. J., Delgado, N. N., Maharjan, R. & Cain, A. K. How antibiotics work together: Molecular mechanisms behind combination therapy. Curr. Opin. Microbiol. 57, 31\u201340 (2020).","journal-title":"Curr. Opin. Microbiol."},{"key":"10393_CR19","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/nyas.14649","volume":"1496","author":"M Zhu","year":"2021","unstructured":"Zhu, M., Tse, M. W., Weller, J., Chen, J. & Blainey, P. C. The future of antibiotics begins with discovering new combinations. Ann. N. Y. Acad. Sci. 1496, 82\u201396 (2021).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10393_CR20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ijmm.2006.01.039","volume":"296","author":"G Yim","year":"2006","unstructured":"Yim, G., Huimi Wang, H. & Davies, J. The truth about antibiotics. Int. J. Med. Microbiol. 296, 163\u2013170 (2006).","journal-title":"Int. J. Med. Microbiol."},{"key":"10393_CR21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1128\/mBio.02270-14","volume":"5","author":"F Baquero","year":"2014","unstructured":"Baquero, F. & Coque, T. M. Widening the spaces of selection: Evolution along sublethal antimicrobial gradients. MBio 5, 5\u20137 (2014).","journal-title":"MBio"},{"key":"10393_CR22","doi-asserted-by":"publisher","unstructured":"Baquero, F. et al. Evolutionary pathways and trajectories in antibiotic resistance. Clin. Microbiol. Rev. 34(4), e0005019. https:\/\/doi.org\/10.1128\/CMR.00050-19 (2021).","DOI":"10.1128\/CMR.00050-19"},{"key":"10393_CR23","unstructured":"EUCAST. Clinical breakpoints\u2014Bacteria (v 11.0). (2021)."},{"key":"10393_CR24","unstructured":"CLSI. CLSI M100-ED30:2020 Performance Standards for Antimicrobial Susceptibility Testing, 30th Edition. Clinical & Laboratory Standards Institute. http:\/\/em100.edaptivedocs.net\/dashboard.aspx. Accessed 26 Oct 2021 (2020)."},{"key":"10393_CR25","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1093\/jac\/dkx113","volume":"72","author":"S Foerster","year":"2017","unstructured":"Foerster, S., Desilvestro, V., Hathaway, L. J., Althaus, C. L. & Unemo, M. A new rapid resazurin-based microdilution assay for antimicrobial susceptibility testing of Neisseria gonorrhoeae. J. Antimicrob. Chemother. 72, 1961\u20131968 (2017).","journal-title":"J. Antimicrob. Chemother."},{"key":"10393_CR26","unstructured":"EUCAST. Antimicrobial susceptibility testing. https:\/\/eucast.org\/ast_of_bacteria\/. Accessed 26 Oct 2021 (2021)."},{"key":"10393_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmicb.2019.01669","volume":"10","author":"JK Palmeiro","year":"2019","unstructured":"Palmeiro, J. K. et al. Molecular epidemiology of multidrug-resistant klebsiella pneumoniae Isolates in a Brazilian Tertiary Hospital. Front. Microbiol. 10, 1\u201311 (2019).","journal-title":"Front. Microbiol."},{"key":"10393_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.00873-18","volume":"62","author":"T Brennan-Krohn","year":"2018","unstructured":"Brennan-Krohn, T., Pironti, A. & Kirby, J. E. Synergistic activity of colistin-containing combinations. Antimicrob. Agents Chemother. 62, 1\u201311 (2018).","journal-title":"Antimicrob. Agents Chemother."},{"key":"10393_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2807\/1560-7917.ES.2016.21.17.30214","volume":"21","author":"MR Fernandes","year":"2016","unstructured":"Fernandes, M. R. et al. Silent dissemination of colistin-resistant Escherichia coli in South America could contribute to the global spread of the mcr-1 gene. Eurosurveillance 21, 1\u20136 (2016).","journal-title":"Eurosurveillance"},{"key":"10393_CR30","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1128\/JCM.00088-14","volume":"52","author":"LN Andrade","year":"2014","unstructured":"Andrade, L. N. et al. Expansion and evolution of a virulent, extensively drug-resistant (polymyxin B-resistant), QnrS1-, CTX-M-2-, and KPC-2-producing Klebsiella pneumoniae ST11 international high-risk clone. J. Clin. Microbiol. 52, 2530\u20132535 (2014).","journal-title":"J. Clin. Microbiol."},{"key":"10393_CR31","unstructured":"EUCAST. Media preparation for EUCAST disk diffusion testing and for determination of MIC values by the broth microdilution method. 1\u20135 (2020)."},{"key":"10393_CR32","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3109\/10408419609106458","volume":"22","author":"A Preston","year":"1996","unstructured":"Preston, A., Mandrell, R. E., Gibson, B. W. & Apicella, M. A. The lipooligosaccharides of pathogenic gram-negative bacteria. Crit. Rev. Microbiol. 22, 139\u2013180 (1996).","journal-title":"Crit. Rev. Microbiol."},{"key":"10393_CR33","doi-asserted-by":"publisher","first-page":"7569","DOI":"10.1128\/IAI.73.11.7569-7577.2005","volume":"73","author":"D Peng","year":"2005","unstructured":"Peng, D., Hong, W., Choudhury, B. P., Carlson, R. W. & Gu, X. X. Moraxella catarrhalis bacterium without endotoxin, a potential vaccine candidate. Infect. Immun. 73, 7569\u20137577 (2005).","journal-title":"Infect. Immun."},{"key":"10393_CR34","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1046\/j.0014-2956.2001.02647.x","volume":"269","author":"EV Vinogradov","year":"2002","unstructured":"Vinogradov, E. V., Duus, J., Brade, H. & Holst, O. The structure of the carbohydrate backbone of the lipopolysaccharide from Acinetobacter baumannii strain ATCC 19606. Eur. J. Biochem. 269, 422\u2013430 (2002).","journal-title":"Eur. J. Biochem."},{"key":"10393_CR35","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/nrc1188","volume":"3","author":"M Guzm\u00e1n","year":"2003","unstructured":"Guzm\u00e1n, M. Cannabinoids: Potential anticancer agents. Nat. Rev. Cancer 3, 745\u2013755 (2003).","journal-title":"Nat. Rev. Cancer"},{"key":"10393_CR36","doi-asserted-by":"publisher","unstructured":"Guard, S. E. et al. Multi-omic analysis reveals cannabidiol disruption of cholesterol homeostasis in human cell lines. 1\u201342 (2020). https:\/\/doi.org\/10.1242\/dev.180224.","DOI":"10.1242\/dev.180224"},{"key":"10393_CR37","unstructured":"Abichabki, N. et al. In Vitro Antibacterial Efficacy of Cannabidiol Plus Polymyxin B: Mixed and Together Against Multidrug-resistant and Polymyxin B-resistant Gram-negative Bacilli. in World Microbe Forum Abstracts (2021)."},{"key":"10393_CR38","first-page":"37","volume":"11","author":"BrCAST","year":"2021","unstructured":"BrCAST. Tabelas de pontos de corte para interpreta\u00e7\u00e3o de CIMs e di\u00e2metros de halos. Braz. Comm. Antimicrob. Susceptibility Test. BrCAST 11, 37\u201340 (2021).","journal-title":"Braz. Comm. Antimicrob. Susceptibility Test. BrCAST"},{"key":"10393_CR39","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.vetmic.2011.12.018","volume":"157","author":"Y Lv","year":"2012","unstructured":"Lv, Y. et al. Systematic mutation analysis of two-component signal transduction systems reveals EsrA-EsrB and PhoP-PhoQ as the major virulence regulators in Edwardsiella tarda. Vet. Microbiol. 157, 190\u2013199 (2012).","journal-title":"Vet. Microbiol."},{"key":"10393_CR40","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1086\/429323","volume":"40","author":"ME Falagas","year":"2005","unstructured":"Falagas, M. E., Kasiakou, S. K. & Saravolatz, L. D. Colistin: The revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin. Infect. Dis. 40, 1333\u20131341 (2005).","journal-title":"Clin. Infect. Dis."},{"key":"10393_CR41","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.cll.2019.04.002","volume":"39","author":"T Brennan-Krohn","year":"2019","unstructured":"Brennan-Krohn, T. & Kirby, J. E. When one drug is not enough: Context, methodology, and future prospects in antibacterial synergy testing. Clin. Lab. Med. 39, 345\u2013358 (2019).","journal-title":"Clin. Lab. Med."},{"key":"10393_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0060666","volume":"8","author":"RP Lamers","year":"2013","unstructured":"Lamers, R. P., Cavallari, J. F. & Burrows, L. L. The efflux inhibitor phenylalanine-arginine beta-naphthylamide (PA\u0392N) permeabilizes the outer membrane of gram-negative bacteria. PLoS ONE 8, 1\u20137 (2013).","journal-title":"PLoS ONE"},{"key":"10393_CR43","unstructured":"U. S. Food and Drug Administration. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD). https:\/\/www.fda.gov\/news-events\/public-health-focus\/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd. Accessed 26 Oct 2021 (2020)."},{"key":"10393_CR44","unstructured":"European Medicines Agency. An overview of Epidyolex and why it is authorised in the EU. (2019)."},{"key":"10393_CR45","unstructured":"ANVISA. Anvisa autoriza primeiro produto \u00e0 base de Cannabis. Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/noticias-anvisa\/2020\/anvisa-autoriza-primeiro-produto-a-base-de-cannabis. Accessed 26 Oct 2021 (2020)."},{"key":"10393_CR46","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00741-5","author":"E Perucca","year":"2020","unstructured":"Perucca, E. & Bialer, M. Critical aspects affecting cannabidiol oral bioavailability and metabolic elimination, and related clinical implications. CNS Drugs https:\/\/doi.org\/10.1007\/s40263-020-00741-5 (2020).","journal-title":"CNS Drugs"},{"key":"10393_CR47","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3390\/ph13090219","volume":"13","author":"SA Millar","year":"2020","unstructured":"Millar, S. A., Maguire, R. F., Yates, A. S. & O\u2019Sullivan, S. E. Towards better delivery of cannabidiol (CBD). Pharmaceuticals 13, 219 (2020).","journal-title":"Pharmaceuticals"},{"key":"10393_CR48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/j.1552-4604.2002.tb05998.x","volume":"42","author":"R Mechoulam","year":"2002","unstructured":"Mechoulam, R., Parker, L. A. & Gallily, R. Cannabidiol: An overview of some pharmacological aspects. J. Clin. Pharmacol. 42, 11\u201319 (2002).","journal-title":"J. Clin. Pharmacol."},{"key":"10393_CR49","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s40263-018-0578-5","volume":"32","author":"L Taylor","year":"2018","unstructured":"Taylor, L., Gidal, B., Blakey, G., Tayo, B. & Morrison, G. A phase I, randomized, double\u2014blind, placebo\u2014controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs 32, 1053\u20131067 (2018).","journal-title":"CNS Drugs"},{"key":"10393_CR50","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41579-020-0420-1","volume":"19","author":"JMV Makabenta","year":"2021","unstructured":"Makabenta, J. M. V. et al. Nanomaterial-based therapeutics for antibiotic-resistant bacterial infections. Nat. Rev. Microbiol. 19, 23\u201336 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"10393_CR51","doi-asserted-by":"publisher","first-page":"122188","DOI":"10.1016\/j.jchromb.2020.122188","volume":"1150","author":"AI Fraguas-S\u00e1nchez","year":"2020","unstructured":"Fraguas-S\u00e1nchez, A. I., Fern\u00e1ndez-Carballido, A., Martin-Sabroso, C. & Torres-Su\u00e1rez, A. I. Stability characteristics of cannabidiol for the design of pharmacological, biochemical and pharmaceutical studies. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 1150, 122188 (2020).","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10393_CR52","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/bph.13895","volume":"175","author":"W Zheng","year":"2018","unstructured":"Zheng, W., Sun, W. & Simeonov, A. Drug repurposing screens and synergistic drug-combinations for infectious diseases. Br. J. Pharmacol. 175, 181\u2013191 (2018).","journal-title":"Br. J. Pharmacol."},{"key":"10393_CR53","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1177\/2168479017694850","volume":"51","author":"JP Jarow","year":"2017","unstructured":"Jarow, J. P., Lurie, P., Ikenberry, S. C. & Lemery, S. Overview of FDA\u2019s expanded access program for investigational drugs. Ther. Innov. Regul. Sci. 51, 177\u2013179 (2017).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"10393_CR54","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.meegid.2013.06.024","volume":"19","author":"EC Cl\u00edmaco","year":"2013","unstructured":"Cl\u00edmaco, E. C. et al. Clonal complexes 104, 109 and 113 playing a major role in the dissemination of OXA-carbapenemase-producing Acinetobacter baumannii in Southeast Brazil. Infect. Genet. Evol. 19, 127\u2013133 (2013).","journal-title":"Infect. Genet. Evol."},{"key":"10393_CR55","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.diagmicrobio.2015.02.011","volume":"82","author":"R Galetti","year":"2015","unstructured":"Galetti, R. et al. Genomic diversification and virulence features in SPM-1-producing Pseudomonas aeruginosa 13 years later. Diagn. Microbiol. Infect. Dis. 82, 179\u2013180 (2015).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10393_CR56","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1128\/AAC.46.8.2720-2722.2002","volume":"46","author":"J Palomino","year":"2002","unstructured":"Palomino, J. et al. Resazurin microtiter assay plate: Simple and inexpensive method for detection of drug resistance in mycobacterium tuberculosis. Antimicrobail. Agents Chemother. 46, 2720\u20132722 (2002).","journal-title":"Antimicrobail. Agents Chemother."},{"key":"10393_CR57","doi-asserted-by":"publisher","first-page":"104445","DOI":"10.1016\/j.micpath.2020.104445","volume":"148","author":"NS Sundaramoorthy","year":"2020","unstructured":"Sundaramoorthy, N. S., Sivasubramanian, A. & Nagarajan, S. Simultaneous inhibition of MarR by salicylate and efflux pumps by curcumin sensitizes colistin resistant clinical isolates of Enterobacteriaceae. Microb. Pathog. 148, 104445 (2020).","journal-title":"Microb. Pathog."},{"key":"10393_CR58","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.2174\/0929867323666160304150522","volume":"23","author":"Y Mahmood","year":"2016","unstructured":"Mahmood, Y., Jamshidi, S., Mark Sutton, J. & Rahman, M. Current advances in developing inhibitors of bacterial multidrug efflux pumps. Curr. Med. Chem. 23, 1062\u20131081 (2016).","journal-title":"Curr. Med. Chem."},{"key":"10393_CR59","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1128\/JCM.01121-14","volume":"52","author":"CD Doern","year":"2014","unstructured":"Doern, C. D. When does 2 plus 2 equal 5? A review of antimicrobial synergy testing. J. Clin. Microbiol. 52, 4124\u20134128 (2014).","journal-title":"J. Clin. Microbiol."},{"key":"10393_CR60","first-page":"2","volume":"2019","author":"T Brennan-Krohn","year":"2019","unstructured":"Brennan-Krohn, T. & Kirby, J. E. Antimicrobial synergy testing by the inkjet printer-assisted automated checkerboard array and the manual time-kill method. J. Vis. Exp. 2019, 2\u20133 (2019).","journal-title":"J. Vis. Exp."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10393-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10393-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10393-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T20:52:38Z","timestamp":1669323158000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10393-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,19]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10393"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-10393-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,19]]},"assertion":[{"value":"27 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JASC is a member of the International Advisory Board of the Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE)\u2014National Health and Medical Research Council (NHMRC). JASC and JECH have received travel support to attend scientific meetings and personal consultation fees from BSPG-Pharm. JASC, JECH, and AWZ are coinventors of the patent \u201cFluorinated CBD compounds, compositions and uses thereof. Pub. No.: WO\/2014\/108899. International Application No.: PCT\/IL2014\/050023,\u201d Def. US number Reg. 62193296; July 29, 2015; INPI on August 19, 2015 (BR1120150164927; Mechoulam R, Zuardi AW, Kapczinski F, Hallak JEC, Guimar\u00e3es FS, Crippa JAS, Breuer A). Universidade de S\u00e3o Paulo (USP) has licensed this patent to Phytecs Pharm (USP Resolution No. 15.1.130002.1.1) and has an agreement with Prati-Donaduzzi to \u201cdevelop a pharmaceutical product containing synthetic CBD and prove its safety and therapeutic efficacy in the treatment of epilepsy, schizophrenia, Parkinson\u2019s disease, and anxiety disorders.\u201d JASC, JECH, and AWZ are coinventors of the patent \u201cCannabinoid-containing oral pharmaceutical composition, method for preparing and using same,\u201d INPI on September 16, 2016 (BR 112018005423-2). The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The other authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6454"}}